The APP protein has been linked with somatic metabolic disorders related to T2D; for example, animal experimental models using App−/− mice have shown higher levels of insulin degrading enzyme (IDE) mRNA, protein and activity in the skeletal muscle as well as lower fasting levels of blood insulin and a larger increase in response to glucose compared to controls [43]. Here, IDE is linked to type 2 diabetes mellitus.